[1]
|
R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, et al., “Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma,” New England Journal of Medicine, Vol. 352, 2005, pp. 987-996. doi:10.1056/NEJMoa043330
|
[2]
|
T. L. Gillison and G. S. Chatta, “Cancer Chemotherapy in the Elderly Patient,” Oncology (Williston Park), Vol. 24, No. 1, 2010, pp. 76-85.
|
[3]
|
L. Balducci, “Pharmacology of Antineoplastic Medications in Older Cancer Patients,” Oncology (Williston Park), Vol. 23, No. 1, 2009, pp. 78-85.
|
[4]
|
A. Hurria and S. M. Lichtman, “Clinical Pharmacology of Cancer Therapies in Older Adults,” British Journal of Cancer, Vol. 98, 2008, pp. 517-522.
doi:10.1038/sj.bjc.6604201
|
[5]
|
S. M. Lichtman, “Pharmacokinetics and Pharmacodynamics in the Elderly,” Clinical Advances in Hematology & Oncology, Vol. 5, 2007, pp. 181-182.
|
[6]
|
D. R. Macdonald, T. L. Cascino, S. C. Schold Jr. and J. G. Cairncross, “Response Criteria for Phase II Studies of Supratentorial Malignant Glioma,” Journal of Clinical Oncology, Vol. 8, 1990, pp. 1277-1280.
|
[7]
|
S. Spiegl-Kreinecker, C. Pirker, M. Filipits, D. Lotsch, J. Buchroithner, J. Pichler, et al., “O6-Methylguanine DNA Methyltransferase Protein Expression in Tumor Cells Predicts Outcome of Temozolomide Therapy in Glioblastoma Patients,” Neuro-Oncology, Vol. 12, No. 1, 2010, pp. 28-36. doi:10.1093/neuonc/nop003
|
[8]
|
J. G. Scott, J. H. Suh, P. Elson, G. H. Barnett, M. A. Vogelbaum, D. M. Peereboom, et al., “Aggressive Treatment Is Appropriate for Glioblastoma Multiforme Patients 70 Years Old or Older: A Retrospective Review of 206 Cases,” Neuro-Oncology, Vol. 13, No. 4, 2011, pp. 428-436. doi:10. 1093/ne uonc/nor005
|
[9]
|
S. E. Combs, J. Wagner, M. Bischof, T. Welzel, F. Wagner, J. Debus, et al., “Postoperative Treatment of Primary Glioblastoma Multiforme with Radiation and Concomitant Temozolomide in Elderly Patients,” International Journal of Radiation Oncology, Biology, Physics, Vol. 70, 2008, pp. 987-992. doi:10.1016/j.ijrobp.2007.07.2368
|
[10]
|
A. Malmstrom, B. H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, H. Schultz, et al., “Temozolomide versus Standard 6-Week Radiotherapy versus Hypofractionated Radiotherapy in Patients Older than 60 Years with Glioblastoma: The Nordic Randomised, Phase 3 Trial,” The Lancet Oncology, Vol. 13, No. 9, 2012, pp. 916-926.
doi:10.1016/S1470-2045(12)70265-6
|
[11]
|
W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, M. Simon, et al., “Temozolomide Chemotherapy Alone versus Radiotherapy Alone for Malignant Astrocytoma in the Elderly: The NOA-08 Randomised, Phase 3 Trial,” The Lancet Oncology, Vol. 13, No. 7, 2012, pp. 707-715. doi:10.1016/S1470-2045(12)70164-X
|
[12]
|
J. Gallego Perez-Larraya, F. Ducray, O. Chinot, I. CatryThomas, L. Taillandier, J. S. Guillamo, et al., “Temozolomide in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial,” Journal of Clinical Oncology, Vol. 29, No. 22, 2011, 3050-3055.
|
[13]
|
R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. Taphoorn, R. C. Janzer, et al., “Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III study: 5-Year Analysis of the EORTC-NCIC Trial,” The Lancet Oncology, Vol. 10, No. 5, 2009, pp. 459-466.
doi:10.1016/S1470-2045(09)70025-7
|
[14]
|
K. L. Chaichana, K. K. Chaichana, A. Olivi, J. D. Weingart, R. Bennett, H. Brem, et al., “Surgical Outcomes for Older Patients with Glioblastoma Multiforme: Preoperative Factors Associated with Decreased Survival, Clinical Article,” Journal of Neurosurgery, Vol. 114, No. 3, 2011, pp. 587-594. doi:10.3171/2010.8.JNS1081
|
[15]
|
A. Mangiola, G. Maira, P. De Bonis, M. Porso, B. Pettorini, G. Sabatino, et al., “Glioblastoma Multiforme in the Elderly: A Therapeutic Challenge,” Journal of NeuroOncology, Vol. 76, No. 2, 2006, pp. 159-163.
doi:10.1007/s11060-005-4711-1
|
[16]
|
K. Abhinav, K. Aquilina, H. Gbejuade, M. La, K. Hopkins and V. Iyer, “A Pilot Study of Glioblastoma Multiforme in Elderly Patients: Treatments, O-6-Methylguanine-DNA Methyltransferase (MGMT) Methylation Status and Survival,” Clinical Neurology and Neurosurgery, Vol. 115, No. 8, 2013, pp. 1375-1378.
doi:10.1016/j.clineuro.2012.12.023
|
[17]
|
R. P. Thomas, L. Recht and S. Nagpal, “Advances in the Management of Glioblastoma: The Role of Temozolomide and MGMT Testing,” Clinical Pharmacology: Advances and Applications, Vol. 5, No. 1, 2013, pp. 1-9.
|
[18]
|
A. Leibetseder, M. Ackerl, B. Flechl, A. Wohrer, G. Widhalm, K. Dieckmann, et al., “Outcome and Molecular Characteristics of Adolescent and Young Adult Patients with Newly Diagnosed Primary Glioblastoma: A Study of the Society of Austrian Neurooncology (SANO),” NeuroOncology, Vol. 15, No. 1, 2013, pp. 112-121.
doi:10.1093/neuonc/nos283
|